This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Why Is Bluebird Bio (BLUE) Stock Gaining Today?
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN). The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.
Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -26.52% and -28.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Humana (HUM) Stock in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second quarter is likely to gain traction from solid individual Medicare Advantage membership growth.
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.
Dopamine and the Weather, Part 2
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics???yet.
Celgene Reports Positive Data on Tecentriq, Abraxane Study
by Zacks Equity Research
Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.
Celgene, Acceleron Report Positive Data on Thalassemia Drug
by Zacks Equity Research
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?
by Zacks Equity Research
Celgene's (CELG) shares decline 21%, in the year-to-date period, on pipeline setbacks. However, we expect a better performance in the second half.
Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst
by Zacks Equity Research
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.
bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA
by Zacks Equity Research
bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.
Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength
by Zacks Equity Research
Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.
Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?
by Zacks Equity Research
Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.
Celgene (CELG) President and COO to Step Down: What's Ahead?
by Zacks Equity Research
Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.
Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate
by Zacks Equity Research
Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Why Sarepta (SRPT) Jumped and We Sold
by Kevin Cook
Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
Healthcare Heroes That Aren't Done Yet
by Kevin Cook
Key growth stocks across medical industries tell you the megatrends are in full force for years to come
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
Recession is Coming! Not
by Kevin Cook
Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk
Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid
by Zacks Equity Research
Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.
Bluebird Up on Buyout Speculation After Celgene/Juno Deal
by Zacks Equity Research
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.
Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion
by Zacks Equity Research
Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.